Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Cipher Mining Inc (CIFR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Cipher Mining Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Cipher Mining Inc trades at $17.94 (market cap $7.14B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.1× Cipher Mining Inc's market cap, and Cipher Mining Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CIFR | |
|---|---|---|
Market Cap | $29.60B | $7.14B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $29.18 |
52-Week Low | $205.48 | $4.72 |
Enterprise Value | $27.56B | $11.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
CIFR trades at $17.87, up 9.43% in 24 hours, but remains in a bearish technical trend with significant fundamental challenges. The company reported a Q2 2026 loss of $0.65 per share, missing estimates, with revenue of $191 million and a net loss of $1.1 billion. Despite negative profitability metrics, analyst consensus is unanimously bullish with a $31.78 price target, citing progress in transitioning from Bitcoin mining to AI data center operations.
The outlook hinges on successful execution of its AI infrastructure pivot, but high valuation ratios and persistent losses pose substantial risks. Near-term support lies at $16, while resistance is at $18. Investor sentiment is divided between optimism over AI contracts and concerns over cash burn and mining dependency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Cipher Mining Inc
Cipher Mining is an industrial-scale technology company focused on Bitcoin mining infrastructure. It develops and operates data centers in the US designed to strengthen the Bitcoin network and support decentralized finance.
Read more on CIFR →
